Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 4/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | DRD5 | P21918 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463280 | 1.00 | AHR (0.48) | AHRPDK2DRD2DRD4DRD3 | |
| SCHEMBL29863302 | 0.82 | NPC1 (0.50) | AHRPDK2HTR1AOPRK1CRBN | |
| SCHEMBL98299 | 0.82 | NPC1 (0.50) | AHRPDK2HTR1AOPRK1CRBN | |
| SCHEMBL18403203 | 0.80 | PNMT (0.43) | AHRPDK2DRD2DRD4DRD3 | |
| SCHEMBL6407953 | 0.79 | MAPT (0.53) | AHRPDK2CRBNPARP1 | |
| SCHEMBL20597383 | 0.78 | MAOA (0.40) | AHRPDK2DRD2DRD4DRD3 | |
| SCHEMBL20597191 | 0.78 | CREBBP (0.38) | AHRPDK2CRBNPARP1WDR91 | |
| SCHEMBL20597531 | 0.77 | PLCG1 (0.45) | AHRPDK2DRD2DRD4DRD3 | |
| SCHEMBL8402074 | 0.76 | BCL2L1 (0.35) | DRD2DRD3DRD1DRD5LMNA | |
| SCHEMBL624585 | 0.76 | CCNB2 (0.54) | AHRPDK2DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079764-B | Synthesis method of sunitinib intermediate 5-fluoroindol-2-one | 山东汇海医药化工有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-112079764-A | Synthesis method of sunitinib intermediate 5-fluoroindole-2-ketone | 山东汇海医药化工有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-111479485-A | Hair dyeing kit and composition for use in hair dyeing kit | 莱雅公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-111334079-A | Full-spectrum high-brightness and high-stability fluorescent dye and synthesis and application thereof | 中国科学院大连化学物理研究所 | 2020-06-26 | — | — | CN | disclosed |
| US-9028562-B2 | Dye composition using a 2-hydroxynaphthalene, (acylamino)phenol or quinoline coupler in a fatty-substance-rich medium, dyeing process and device therefor | L'OREAL (FR) | 2015-05-12 | — | — | US | disclosed |
| US-9028562-B2 | Dye composition using a 2-hydroxynaphthalene, (acylamino)phenol or quinoline coupler in a fatty-substance-rich medium, dyeing process and device therefor | L'OREAL (FR) | 2015-05-12 | — | — | US | disclosed |
| US-20140041133-A1 | DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR | L'OREAL (FR) | 2014-02-13 | — | — | US | disclosed |
| US-20140041133-A1 | DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR | L'OREAL (FR) | 2014-02-13 | — | — | US | disclosed |
| US-20100158842-A1 | NATURAL SKIN WHITENER: 4-HYDROXY-OXINDOLE-3-ACETIC ACID | SPECTRUM DYNAMICS LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-6506901-B2 | 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma | WYETH | 2003-01-14 | — | — | US | disclosed |
| WO-2002038543-A2 | 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002038544-A2 | 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-16 | — | — | WO | disclosed |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006255-A2 | HYDROXY-(PIPERIDIN-4-YL-METHYLAMINO)-ALKYL BETA-3 ADRENERGIC RECEPTOR ANTAGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| JP-2001226351-A | METHOD FOR PRODUCING 4-HYDROXYOXYINDOLE | DAISO CO LTD | 2001-08-21 | — | — | JP | disclosed |
| WO-1994003425-A2 | CARBOSTYRIL DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIA | SYNTEX (U.S.A.) INC. (US) | 1994-02-17 | — | — | WO | disclosed |
| US-4622336-A | ANALGESICS | SANDOZ LTD. (CH) | 1986-11-11 | — | — | US | disclosed |
| WO-1983002610-A1 | DERIVATIVES OF 3,3-DIALKYL-INDOLIN AND OF 3,3-ALKYLENE-INDOLIN, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | SANDOZ AG (CH) | 1983-08-04 | — | — | WO | disclosed |
| US-3965095-A | Oxindole derivatives | SANDOZ LTD. (CH) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140041133-A1 | DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR | HADHB, HADH, FABP4 | AHR 5/4885PDK2 738/4885DRD2 1745/4885 |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB2 | AHR 225/4885PDK2 2998/4885DRD2 325/4885 |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | AHR 259/4885PDK2 576/4885DRD2 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.